Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5644 | Ordered by Date (descending)
1 2 3 ... 55 56 57  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Monte Rosa Therapeutics–1AB Media: public relations, 202009 service existent by 1AB Media 2020-09-24
Monte Rosa Therapeutics–Aisling Capital: investment, 202009 financing round Series B totalling $96m incl new + lead investor Aisling Capital 2020-09-24
Monte Rosa Therapeutics–Alphabet: investment, 202009 financing round Series B totalling $96m incl new + co-investor GV 2020-09-24
Monte Rosa Therapeutics–Amzak Health: investment, 202009 financing round Series B totalling $96m incl new + co-investor Amzak Health 2020-09-24
Monte Rosa Therapeutics–Cambridge Asset Management: investment, 202009 financing round Series B totalling $96m incl new + co-investor CAM 2020-09-24
Monte Rosa Therapeutics–Casdin Capital: investment, 202009 financing round Series B totalling $96m incl new + co-investor Casdin Capital 2020-09-24
Monte Rosa Therapeutics–Cormorant Asset Managment: investment, 202009 financing round Series B totalling $96m incl new + co-investor Cormorant 2020-09-24
Monte Rosa Therapeutics–HBM: investment, 202009 financing round Series B totalling $96m incl new + co-investor HBM Healthcare Investments 2020-09-24
Monte Rosa Therapeutics–New Enterprise Associates: investment, 202009 financing round Series B totalling $96m incl existing + co-investor NEA 2020-09-24
Monte Rosa Therapeutics–SEVERAL: investment, 202009 financing round Series B $96m led by AIsling Capital 2020-09-24
Monte Rosa Therapeutics–Sixty Degree Capital: investment, 202009 financing round Series B totalling $96m incl new + co-investor Sixty Degree Capital 2020-09-24
Monte Rosa Therapeutics–Versant Ventures: investment, 202009 financing round Series B totalling $96m incl existing + co-investor Versant Ventures 2020-09-24
AM-Pharma–Bellevue: investment, 202009 existent portfolio company of BB Pureos Bioventures LP 2020-09-23
Bellevue–SEVERAL: investment, 202009 Closing $170m of BB Pureos Bioventures LP fund 2020-09-23
ImCheck Therapeutics–Bellevue: investment, 202009 existent portfolio company of BB Pureos Bioventures LP 2020-09-23
Jennewein Biotechnologie–Chr. Hansen: investment, 202009– acquisition €310m on debt-free basis ANNOUNCED 2020-09-22
Salvia BioElectronics–SEVERAL: investment, 202009 financing round Series A €21m co-led by Panakès Partners + Inkef Capital + SHS 2020-09-22
Salvia BioElectronics–SHS: investment, 202009 financing round Series A totalling €21m incl new + co-lead investor SHS 2020-09-22
Lava Therapeutics–Bellevue: investment, 202009 financing round Series C totalling $83m incl new + co-investor BB Pureos Bioventures 2020-09-17
Lava Therapeutics–SEVERAL: investment, 202009 financing round Series C $83m co-led by Novo Ventures + Sanofi Ventures 2020-09-17
Novartis–BioNTech: investment, 202009– acquisition of Novartis GMP Biologics Manufacturing Site in Marburg by BioNTech 2020-09-17
Dinaqor–KWM Communications: public relations, 202009 service existent by KWM Communications 2020-09-16
Moderna–Cabinet Privé de Conseils: public relations, 202009 service existent CPC is Swiss media contact 2020-09-16
Evotec–BIOASTER: antiinfectives, 202009– collab research to establish tech + innovation hub in Lyon work started in early 2020 2020-09-14
Boehringer–Click Therapeutics: digital therapeutics, 202009– collab ufpront+milestones >$500m + royalties ww dev+marketing CT-155 for schizophrenia 2020-09-11
Canopy Biosciences–Bruker: investment, 202009 acquisition €na of Canopy Biosciences LLC by Bruker Corp 2020-09-11
Oncomfort–SEVERAL: investment, 202009 financing round Series A €10m co-led by Debiopharm + Crédit Mutuel Innovation 2020-09-09
Boehringer–BiomX: biomarker discovery, 202009– collab discovery of microbiome-based biomarkers for IBD using XMarker platform 2020-09-02
Evotec–Univ Oxford: biobanking, 202009– collab €na granting Evotec access to QUOD biobank for multi-omics analyses for drug discovery 2020-09-02
BioVersys–SEVERAL: investment, 202009 financing round Series B CHF19m 2020-09-01
Helmholtz–Bruker: NMR spectrometer, 202009c supply 1.2 GHz NMR spectrometer with 28 Tesla to FZ Jülich 2020-09-01
Switzerland (govt)–Moderna: mRNA-based vaccines, 202009c– contract for supply of 4.5m doses of Covid-19 vaccine candidate mRNA-1273 2020-09-01
Aimmune Therapeutics–Nestlé: investment, 202008– cash tender offer for all remaining shares at $34.5/share representing total equity value of $2.6b 2020-08-31
Semalytix–SEVERAL: investment, 202008 financing round Series A €4.3m co-led by btov + Fly Ventures 2020-08-31
Aignostics–Berlin (govt): investment, 202008 seed financing round totalling €5m incl co-investor VC Fonds Technologie der IBB 2020-08-28
Aignostics–Boehringer: investment, 202008 seed financing round totalling €5m incl lead investor BIVF 2020-08-28
Aignostics–Hessen (govt): investment, 202008 seed financing round totalling €5m incl co-investor Future Capital 2020-08-28
Aignostics–High-Tech Gründerfonds: investment, 202008 seed financing round totalling €5m incl co-investor HTGF 2020-08-28
Aignostics–SEVERAL: investment, 202008 seed financing round €5m led by BIVF + incl HTGF + IBB VC Fonds Technologie + Future Capital 2020-08-28
Triumvira Immunologics–Bayer: investment, 202008 financing round Series A totalling $55m incl new + co-lead investor Leaps by Bayer 2020-08-27
Triumvira Immunologics–SEVERAL: investment, 202008 financing round Series A $55m co-led by Leaps by Bayer + Northpond Ventures 2020-08-27
Freenome–SEVERAL: investment, 202008 financing round Series C $270m co-led by Bain Capital Life Sciences + Perceptive Advisors 2020-08-26
Univ Guelph–Bruker: NMR spectrometer, 202008 supply existent of 400 MHz NMR spectrometer + Fourier 80 benchtop NRM system 2020-08-24
Scienion–Cellink: investment, 202008– acquisition €80m on cash/debt-free basis with €40m in shares + €40m in shares 2020-08-19
CureVac–Hopp Group: investment, 202008 private placement €100m at $16/share to DH-LT-Investments GmbH + affiliates 2020-08-18
Bayer–Hua Medicine: dorzagliatin, 202008– commercialisation agreement + strategic partnership in China 2020-08-17
F2G Ltd–Advent Venture Partners: investment, 202008 financing round totalling $60.8m incl exisiting investor Advent Life Sciences 2020-08-12
F2G Ltd–Cowen: investment, 202008 financing round totalling $60.8m incl new investor Cowen Healthcare Investments 2020-08-12
F2G Ltd–EMS (BR): investment, 202008 financing round totalling $60.8m incl exisiting investor Brace Pharma Capital 2020-08-12
F2G Ltd–Morningside: investment, 202008 financing round totalling $60.8m incl exisiting investor Morningside Ventures 2020-08-12
F2G Ltd–Novo Group: investment, 202008 financing round totalling $60.8m incl exisiting investor Novo Ventures 2020-08-12
F2G Ltd–SEVERAL: investment, 202008 financing round $60.8m from new investor Cowen Healthcare Investments + existing investors 2020-08-12
Atriva Therapeutics–High-Tech Gründerfonds: credit, 202008– convertible loan financing round totalling €8.6m incl existing + co-lead investor HTGF 2020-08-11
Atriva Therapeutics–Meneldor: credit, 202008– convertible loan financing round totalling €8.6m incl existing + co-lead investor Meneldor BV 2020-08-11
Atriva Therapeutics–SEVERAL: credit, 202008– convertible loan financing round €8.6m led by existing investors Meneldor + HTGF 2020-08-11
Bayer–Atomwise: AI-based drug discovery, 202008 collab existent 2020-08-11
Bayer–Linklaters: legal services, 202008 supply service legal counsel with regard to acquisition of Kandy Therapeutics by Bayer 2020-08-11
Bayer–Morgan Stanley: financial services, 202008 supply service financial advisor with regard to acquisition of Kandy Therapeutics by Bayer 2020-08-11
Kandy Therapeutics–Bayer: investment, 202008– acquisition $425m upfront + $450m developm milestones + triple digit $m sales milestones 2020-08-11
Kandy Therapeutics–Goldman Sachs: financial services, 202008 supply service financial advisor with regard to acquisition of Kandy Tx by Bayer 2020-08-11
Kandy Therapeutics–Goodwin Procter: legal services, 202008 supply service legal counsel with regard to acquisition of Kandy Therapeutics by Bayer 2020-08-11
CureVac–SEVERAL: investment, 202008 IPO $245.3m with 13.3m+2m common shares at $16/share at Nasdaq Global Market 2020-08-10
Immunic–SEVERAL: investment, 202008 underwritten public offering $90m+$13.5m with 5m+750k shares common stock at $18/share 2020-08-10
T-Knife–Andera Partners: investment, 202008 financing round Series A totalling €66m incl existing + co-investor Andera Partners 2020-08-06
T-Knife–Boehringer: investment, 202008 financing round Series A totalling €66m incl existing + co-investor BIVF 2020-08-06
T-Knife–RA Capital Management: investment, 202008 financing round Series A totalling €66m incl new + co-lead investor RA Capital 2020-08-06
T-Knife–SEVERAL: investment, 202008 financing round Series A €66m co-led by Versant Ventures + RA Capital 2020-08-06
T-Knife–Versant Ventures: investment, 202008 financing round Series A totalling €66m incl new + co-lead investor Versant Ventures 2020-08-06
GentiBio–Novartis: investment, 202008 seed financing round totalling $20m inbcl co-lead investor Novartis Venture Fund 2020-08-05
GentiBio–SEVERAL: investment, 202008 seed financing round $20m led by OrbiMed + Novartis Venture + RA Capital Management 2020-08-05
Matterhorn Biosciences–Versant Ventures: investment, 202008– seed financing $30m commitment from Versant Ventures 2020-08-05
NBE Therapeutics–Optimum Strategic Communications: public relations, 202008 service existent by Optimum 2020-08-03
Varian Medical Systems–Siemens: investment, 202008– acquisition $16.4b in cash of Varian Medical Systems Inc by Siemens Healthineers AG ANNOUNCED 2020-08-02
DNA Script–SEVERAL: investment, 202007 financing round Series B extension $50m led by Casdin Capital 2020-07-29
Vesigen Therapeutics–Bayer: investment, 202007 financing round Series A totalling $28.5m incl co-lead investor Leaps by Bayer 2020-07-22
Vesigen Therapeutics–SEVERAL: investment, 202007 financing round Series A $28.5m co-led by Leaps by Bayer + Morningside Ventures 2020-07-22
Quantro Therapeutics–Boehringer: investment, 202007 seed financing round from BIVF + Evotec acquiring equal minority stakes 2020-07-21
Quantro Therapeutics–Evotec: drug discovery services, 202007– supply of hit identification services by Evotec 2020-07-21
Quantro Therapeutics–Evotec: investment, 202007 seed financing round from BIVF + Evotec acquiring equal minority stakes 2020-07-21
Quantro Therapeutics–MC Services: public relations, 202007 service existent by MC Services 2020-07-21
Quantro Therapeutics–SEVERAL: investment, 202007 seed financing round from BIVF + Evotec acquiring equal minority stakes 2020-07-21
Tubulis–Bavaria (govt): investment, 202007 financing round Series A totalling €10.7m incl co-investor Bayern Kapital 2020-07-21
Tubulis–BioMedPartners: investment, 202007 financing round Series A totalling €10.7m incl co-lead investor BioMedPartners 2020-07-21
Tubulis–BPCE: investment, 202007 financing round Series A totalling €10.7m incl co-investor Seventure Partners 2020-07-21
Tubulis–Germany (govt): investment, 202007 financing round Series A totalling €10.7m incl co-investor Coparion 2020-07-21
Tubulis–High-Tech Gründerfonds: investment, 202007 financing round Series A totalling €10.7m incl co-lead investor HTGF 2020-07-21
Tubulis–Occident Group: investment, 202007 financing round Series A totalling €10.7m incl co-investor Occident Group 2020-07-21
Tubulis–SEVERAL: investment, 202007 financing round Series A €10.7m co-led by BioMedPartners + HTGF 2020-07-21
Tubulis–Trophic Communications: public relations, 202007 service existent by Trophic Communications 2020-07-21
TeleClinic–Zur Rose Group: investment, 202007– acquisition of TeleClinic GmbH for mid-double-digit million EUR price by Zur Rose Group 2020-07-16
Enancio–Illumina: acquisition, 202007 acquisition of Enancio by Illumina 2020-07-14
Anergis–Virometix: allergy immunotherapy, 202007– collab research study at HZI using SVLPs supported by TRANSVAC2 grant in house dust mite allergy 2020-07-09
CirQuest Labs–MLM Medical Labs: investment, 202007 acquisition of CirQuest Labs by MLM Medical Labs 2020-07-08
Osivax–Trophic Communications: public relations, 202007 service existent by Trophic Communications 2020-07-08
Sanofi–Kiadis: NK cell therapy, 202007– license ww excl for K-NK004 program + two other programs €17.5m upfront + €857.5m milestones + royalties 2020-07-08
Resistell–EU (govt): grant, 202007 up to €2.5m grant + equity financing offer from EIC programme/fund 2020-07-03
Resolution Spectra Systems–Merck (DE): investment, 202007 acquisition €na of Resolution Spectra Systems by Merck 2020-07-01
Roche–Inveox: sample management software, 202007– collab digitization Vantage Workflow Solution for histopathology labs with Roche Diagnostics 2020-07-01
Waters–Heidrick & Struggles: recruitment services, 202007 supply service placement of Udit Batra as CEO of Waters 2020-07-01
CRISPR Therapeutics–SEVERAL: investment, 202006– public offering $450m+67.5m with 6.43m+964.3k common shares at $70/share 2020-06-29
1 2 3 ... 55 56 57  next pagenext page



Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [iito] Made Without Love 650x80px

» top